157 related articles for article (PubMed ID: 37305048)
1. Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy.
Yang Z; Di Y; Ye J; Yu W; Guo Z
Front Endocrinol (Lausanne); 2023; 14():1171628. PubMed ID: 37305048
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy.
Li B; Li MD; Ye JJ; Chen Z; Guo ZJ; Di Y
Chin Med J (Engl); 2020 Mar; 133(6):664-669. PubMed ID: 32068603
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Conbercept Injection as an Adjuvant in Vitrectomy with Silicone Oil Infusion for Severe Proliferative Diabetic Retinopathy.
Gao S; Lin Z; Chen Y; Xu J; Zhang Q; Chen J; Shen X
J Ocul Pharmacol Ther; 2020 Jun; 36(5):304-310. PubMed ID: 32186940
[No Abstract] [Full Text] [Related]
4. Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy.
Wang W; Qu C; Yan H
Front Endocrinol (Lausanne); 2023; 14():1098165. PubMed ID: 36896181
[TBL] [Abstract][Full Text] [Related]
5. Effect of Intravitreal Conbercept Injection on Complications of Pars Plana Vitrectomy in Patients with Proliferative Diabetic Retinopathy.
Ding Y; Su N; Luan J; Ni Y; Sun Z
J Pers Med; 2023 Mar; 13(4):. PubMed ID: 37108958
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal conbercept as an adjuvant in vitrectomy for proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials.
Chen GH; Tzekov R; Mao SH; Tong YH; Jiang FZ; Li WS
Eye (Lond); 2022 Mar; 36(3):619-626. PubMed ID: 33824510
[TBL] [Abstract][Full Text] [Related]
7. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study.
Jiang T; Gu J; Zhang P; Chen W; Chang Q
BMC Ophthalmol; 2020 Feb; 20(1):43. PubMed ID: 32013913
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
Smith JM; Steel DH
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
[TBL] [Abstract][Full Text] [Related]
9. Pars plana vitrectomy assisted by intravitreal injection of conbercept enhances the therapeutic effect and quality of life in patients with severe proliferative diabetic retinopathy.
Wang Q; Cai H; Xu D; Cui L; Zhang Y; Chen M
Am J Transl Res; 2022; 14(2):1324-1331. PubMed ID: 35273734
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage.
Li S; Yang Y; Zou J; Zeng J; Ding C
BMC Ophthalmol; 2022 Feb; 22(1):63. PubMed ID: 35139812
[TBL] [Abstract][Full Text] [Related]
11. Monitoring intraocular proangiogenic and profibrotic cytokines within 7 days after adjunctive anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy.
Hu Z; Cao X; Chen L; Su Y; Ji J; Yuan S; Fransisca S; Mugisha A; Zou W; Xie P; Liu Q
Acta Ophthalmol; 2022 May; 100(3):e726-e736. PubMed ID: 34260829
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy.
Mao JB; Wu HF; Chen YQ; Zhao SX; Tao JW; Zhang Y; Zheng B; Wang L; Shen LJ
Int J Ophthalmol; 2018; 11(7):1217-1221. PubMed ID: 30046542
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy.
Hu L; Chen Q; Du Z; Wang W; Zhao G
Int Ophthalmol; 2021 May; 41(5):1635-1642. PubMed ID: 33538931
[TBL] [Abstract][Full Text] [Related]
15. Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study.
Yao TT; Yang Y; Jin XL; Wang YX; Zhou YL; Xu AJ; He FL; Wang ZY
Acta Ophthalmol; 2020 Nov; 98(7):e795-e800. PubMed ID: 32114709
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of angiogenic factors in aqueous humor associated with less intraoperative bleeding in PDR patients with NVG receiving conbercept: a randomized controlled trial.
Xu Q; Gong C; Qiao L; Feng R; Liu H; Liu Y; Yang L; Fan W; Guan L; Li J; Zhang Y; Li S
BMC Ophthalmol; 2022 May; 22(1):224. PubMed ID: 35585570
[TBL] [Abstract][Full Text] [Related]
17. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.
Gupta A; Bansal R; Gupta V; Dogra MR
Int Ophthalmol; 2012 Apr; 32(2):135-44. PubMed ID: 22450558
[TBL] [Abstract][Full Text] [Related]
18. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
19. INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY.
Su L; Ren X; Wei H; Zhao L; Zhang X; Liu J; Su C; Tan L; Li X
Retina; 2016 May; 36(5):938-43. PubMed ID: 26630313
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal conbercept improves outcome in patients undergoing vitrectomy for proliferative diabetic retinopathy: A systematic review and meta-analysis.
Pranata R; Vania A
J Evid Based Med; 2020 May; 13(2):116-124. PubMed ID: 32167242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
